Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing Non-IPF Interstitial Lung Diseases

被引：0
|
作者：
Torrisi, S. [1 ,2 ,3 ]
Kahn, N. C. [1 ,2 ,3 ]
Waelscher, J. [1 ,2 ,3 ]
Sarmand, N. [1 ,2 ,3 ]
Polke, M. [1 ,2 ,3 ]
Heussel, C. [2 ,3 ,4 ]
Palmucci, S. [5 ]
Sambataro, G. [6 ]
Vancheri, C. [6 ]
Kreuter, M. [1 ,2 ,3 ]
机构：
[1] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis, Thoraxklin, Heidelberg, Germany
[2] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany
[3] German Ctr Lung Res, Heidelberg, Germany
[4] Heidelberg Univ, Thoraxklin, Radiol, Heidelberg, Germany
[5] Univ Hosp, Dept Med Surg Sci & Adv Technol, Radiol Unit 1, Catania, Italy
[6] Univ Catania, Dept Clin & Expt Med, Reg Referral Ctr Rare Lung Dis, AOU Policlin Vittorio Emanuele, Catania, Italy
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4765
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases
    Zanini, Umberto
    Luppi, Fabrizio
    Kaur, Karina
    Anzani, Niccolo
    Franco, Giovanni
    Ferrara, Giovanni
    Kalluri, Meena
    Mura, Marco
    RESPIROLOGY, 2024, 29 (05) : 387 - 395
  • [22] Use of 6-min walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases
    Zanini, Umberto
    Luppi, Fabrizio
    Kaur, Karina
    Anzani, Nicolo
    Franco, Giovanni
    Ferrara, Giovanni
    Kalluri, Meena
    Mura, Marco
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [23] Defining and predicting progression in non-IPF interstitial lung disease
    Goos, Tinne
    De Sadeleer, Laurens J.
    Yserbyt, Jonas
    De Langhe, Ellen
    Dubbeldam, Adriana
    Verbeken, Erik K.
    Verleden, Geert M.
    Vermant, Marie
    Verschakelen, Johny
    Vos, Robin
    Weynand, Birgit
    Verleden, Stijn E.
    Wuyts, Wim A.
    RESPIRATORY MEDICINE, 2021, 189
  • [24] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Fabre, Aurelie
    Nicholson, Andrew G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08): : 780 - 780
  • [25] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Walsh, S. L. F.
    Inoue, Y.
    Richeldi, L.
    Kolb, M.
    Tetzlaff, K.
    Stowasser, S.
    Coeck, C.
    Clerisme-Beaty, E.
    Rosenstock, B.
    Quaresma, M.
    Haeufel, T.
    Goeldner, R-G
    Schlenker-Herceg, R.
    Brown, K. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1718 - 1727
  • [26] A real-life cohort of antifibrotic-treated non-IPF progressive pulmonary fibrosis patients
    Renner, A.
    Vertanen, E.
    Sutinen, E.
    Ainola, M.
    Myllaerniemi, M.
    Hollmen, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S552 - S552
  • [27] Nintedanib in progressive fibrosing interstitial lung diseases
    Hadjiski, D.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (04): : 393 - 394
  • [28] Patterns of progression in non-IPF fibrotic interstitial lung disease
    Wells, Athol U.
    CURRENT OPINION IN PULMONARY MEDICINE, 2023, 29 (05) : 459 - 464
  • [29] The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
    Sarkar, Paroma
    Avram, Cristina
    Chaudhuri, Nazia
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (10) : 1001 - 1008
  • [30] Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
    Cottin, Vincent
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153):
12345